News | Proton Therapy | August 06, 2019

IBA Signs Contract to Install Proton Therapy Center in Kansas

Construction to host IBA’s Proteus One system expected to start later this year

IBA Signs Contract to Install Proton Therapy Center in Kansas

August 6, 2019 — IBA (Ion Beam Applications S.A.) recently signed a contract and received the first payment for a Proteus One solution with The University of Kansas Health System. The contract includes a plan for a possible extension with a second ProteusOne unit in the future. The proton therapy center will be built at the Main Campus of The University of Kansas Health System in Kansas City, Kansas. Construction is anticipated to begin later this year.

The contract includes a long-term operation and maintenance agreement and the typical end-user price for a Proteus One solution, with a maintenance contract between EUR 35 and 40 million. IBA will begin to recognize revenue for the contract in the 2019 financial year.

Bob Page, president and chief executive officer  of The University of Kansas Health System commented, “We are excited to partner with IBA, the world’s leading proton therapy system provider, to bring proton therapy to Kansas City and the region. IBA’s Proteus One represents one of the most advanced solutions to delivering proton therapy. With the first system in place, and the ability to add a second system in the future, patients will be able to stay closer to home to receive the most advanced cancer care available.”

Proteus One is the compact intensity modulated proton therapy (IMPT) solution from IBA, benefiting from the latest technologies. The system is smaller, more affordable, easier to install and to operate.

For more information: www.iba-worldwide.com

Related Content

Accuray Incorporated announced that Mercy Hospital St. Louis continues to demonstrate its commitment to improving patient outcomes with the installation of the first CyberKnife M6 System in Missouri at their state-of-the-art David C. Pratt Cancer Center
News | Stereotactic Body Radiation Therapy (SBRT) | February 27, 2020
February 27, 2020 — Accuray Incorporated announced that Mercy
An example of the MRI scans showing long-term and short-term survival indications. #MRI

An example of the MRI scans showing long-term and short-term survival indications. Image courtesy of Case Western Reserve University

News | Magnetic Resonance Imaging (MRI) | February 21, 2020
February 21, 2020 — ...
Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure

Arizona State University researchers (in collaboration with Banner MD Anderson Cancer Center) have discovered a biocompatible cost-effective hydrogel that can be used to monitor therapeutic doses of ionizing radiation by becoming more pink with increasing radiation exposure. This picture shows a circle of hydrogel that was irradiated on the left half, which is slightly pink; whereas the right half of the gel is not irradiated and remains colorless.

News | Radiation Therapy | February 18, 2020
February 18, 2020 — More than half of all cancer patients undergo radiation therapy and the dose is critical.
Nuclear imaging equipment growth in 2020
News | Nuclear Imaging | February 14, 2020
February 14, 2020 — The nuclear imaging equipment
Varian announced it has received FDA 510(k) clearance for its Ethos therapy, an Adaptive Intelligence solution. Ethos therapy is an artificial intelligence (AI)-driven holistic solution that provides an opportunity to transform cancer care.
News | Image Guided Radiation Therapy (IGRT) | February 11, 2020
February 11, 2020 — Varian announced it has received FDA 510(k) c
The radiation therapy market is projected to grow in through 2026

Image courtesy of Accuray

News | Proton Therapy | February 10, 2020
February 10, 2020 — Amid technological advancement, and notable research and development activities, the global ...
SIR President Laura Findeiss, M.D., FSIR

SIR President Laura Findeiss, M.D., FSIR

News | Interventional Radiology | February 09, 2020
February 9, 2020 — For some patients, kidney cancer can be effectively treated without surgery, according to the...
Accuray TomoTherapy total body irradiation
News | Radiation Therapy | February 07, 2020
February 7, 2020 — Accuray Incorporated announced that two new studies demonstrate the benefits of the ...
Purdue University-discovered fluorescent markers to target and illuminate cancer during surgery, has announced the results of a multi-institutional Phase 2 clinical trial in which outcomes were improved for 26 percent of patients undergoing pulmonary resection for non-small-cell lung cancer (NSCLC)

A Purdue discovery being developed by On Target Laboratories Inc., illuminates lung cancer cells on a patient during surgery. The “fluorescent markers” help medical professionals identify and remove cancer cells during surgery and is shown to improve outcomes. The technology is beginning Phase 3 clinical trials. (Photo provided by On Target)

News | Molecular Imaging | February 06, 2020
February 6, 2020 — ...